{"id":16332,"date":"2026-06-06T23:58:33","date_gmt":"2026-06-06T20:58:33","guid":{"rendered":"https:\/\/imgist.ru\/v-hode-issledovaniya-bylo-pokazano-chto-ispolzovanie-glyukometra-dexcom-prinosit-polzu-paczientam-s-diabetom-ne-poluchayushhim-insulin\/"},"modified":"2026-06-06T23:58:33","modified_gmt":"2026-06-06T20:58:33","slug":"tadqiqot-shuni-korsatdiki-dexcom-glyukometridan-foydalanish-insulin-qabul-qilmaydigan-diabet-bilan-ogrigan-bemorlarga-foyda-keltiradi","status":"publish","type":"post","link":"https:\/\/imgist.ru\/uz\/v-hode-issledovaniya-bylo-pokazano-chto-ispolzovanie-glyukometra-dexcom-prinosit-polzu-paczientam-s-diabetom-ne-poluchayushhim-insulin\/","title":{"rendered":"Tadqiqot shuni ko&#039;rsatdiki, Dexcom glyukometridan foydalanish insulin qabul qilmaydigan diabet bilan og&#039;rigan bemorlar uchun foydalidir."},"content":{"rendered":"<p>Muallif: Sneha SK<\/p>\n<p> 6-iyun (Reuters) - Tibbiy asboblar ishlab chiqaruvchi Dexcom kompaniyasining ma&#039;lum qilishicha, o&#039;zining G7 uzluksiz glyukoza monitoringi tizimidan foydalanish odatdagi parvarishga nisbatan insulin ishlatmaydigan 2-toifa diabetli bemorlarda qon shakarini nazorat qilishni yaxshilagan.<\/p>\n<p> Natijalar shanba kuni Amerika Diabet Assotsiatsiyasi konferensiyasida taqdim etildi.<\/p>\n<p> Tadqiqotdan batafsil ma&#039;lumot:<\/p>\n<p> \u2022 26 haftalik tadqiqotda insulin qabul qilmagan 283 diabetga chalingan bemor ishtirok etdi. Ularning yarmi Dexcom G7 qurilmasidan foydalangan, qolgan yarmi esa qondagi glyukoza miqdorini mustaqil ravishda nazorat qilgan. Ishtirokchilarning aksariyati metformin, GLP-1 va SGLT2 kabi keng tarqalgan diabetga qarshi dorilarni qabul qilishgan.<\/p>\n<p> \u2022 Dexcom G7 dan foydalangan ishtirokchilar 26 haftadan so&#039;ng qon shakarining o&#039;rtacha 1,6% ga pasayishini boshdan kechirdilar, bu o&#039;z-o&#039;zini nazorat qilish usulidan foydalanganlarga qaraganda 0,9% ga ko&#039;p edi.<\/p>\n<p> \u2022 \u00abUmid qilamizki, bu (davolash standartiga) sezilarli ta\u2019sir ko\u00bbrsatadi va 2-toifa diabetga chalingan barcha odamlar, jumladan, insulin qabul qilmaydiganlar uchun uzluksiz glyukoza monitoringi tizimlaridan foydalanishni yaxshilaydi\u201d, dedi Kolorado Anschutz universiteti professori va tadqiqotning bosh tadqiqotchisi Tamara Oser Reuters agentligiga.<\/p>\n<p> \u2022 Doimiy glyukoza monitoringi moslamalari qon shakar darajasini barmoqni sanchmasdan kuzatib boradigan kiyiladigan qurilmalardir. Xabardorlikning ortishi, sug&#039;urta qamrovining kengayishi va ulardan foydalanish qulayligi Dexcom G7 kabi qurilmalarning joriy etilishiga turtki bo&#039;lmoqda.<\/p>\n<p> \u2022 Tadqiqot shuni ko&#039;rsatdiki, Dexcom G7 dan foydalanish keng tarqalgan diabetga qarshi dorilar bilan birgalikda qo&#039;llanilganda qon shakar darajasini qo&#039;shimcha ravishda pasaytirgan.<\/p>\n<p> \u2022 GLP-1 qo&#039;shimchalarini qabul qilgan ishtirokchilar orasida Dexcom G7 dan foydalanayotganlarda qon shakarining 1,4% ga kamayishi kuzatildi, nazorat guruhida esa bu ko&#039;rsatkich 0,2% ga kamaydi.<\/p>\n<p> \u2022 &quot;...bu foydalanuvchilar uchun bu yerda sezilarli foyda borligiga ishonchli dalillarni taqdim etadi. Menimcha, klinik hamjamiyat, sog&#039;liqni saqlash tizimi va to&#039;lovchilar bunga erishilganda ham sog&#039;liq uchun, ham iqtisodiy foydani ko&#039;rishadi&quot;, dedi Dexcom bosh direktori Jeyk Lich Reuters agentligiga.<\/p>\n<p> \u2022 Bu natijalar &quot;Qo&#039;shma Shtatlarda va butun dunyoda yangi tibbiy yordam standartini o&#039;rnatishga yordam beradi&quot;, dedi u bayonotida.<\/p>\n<p> \u2022 Hozirda tadqiqotning olti oylik uzaytirish bosqichi davom etmoqda, bu 12 oygacha bo&#039;lgan ma&#039;lumotlarni taqdim etadi.<\/p>\n<p> (Bengalurudagi Sneha S.K. xabari; Shreya Biswas tomonidan tahrirlangan)<\/p>","protected":false},"excerpt":{"rendered":"<p>Sneha SK tomonidan 6-iyun (Reuters) - Tibbiy asboblar ishlab chiqaruvchi Dexcom o&#039;zining G7 uzluksiz glyukoza monitoringi tizimidan foydalanish yaxshilanganini aytdi...<\/p>","protected":false},"author":1,"featured_media":16333,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-16332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","hvn-theme-has-thumbnail"],"_links":{"self":[{"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/posts\/16332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/comments?post=16332"}],"version-history":[{"count":0,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/posts\/16332\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/media\/16333"}],"wp:attachment":[{"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/media?parent=16332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/categories?post=16332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imgist.ru\/uz\/wp-json\/wp\/v2\/tags?post=16332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}